Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Sees Significant Growth in Short Interest

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 16,586 shares, a growth of 51.0% from the July 15th total of 10,987 shares. Approximately 3.3% of the company’s stock are short sold. Based on an average daily volume of 80,891 shares, the short-interest ratio is currently 0.2 days.

Eloxx Pharmaceuticals Stock Down 0.5%

Shares of Eloxx Pharmaceuticals stock opened at $18.16 on Thursday. The stock’s fifty day simple moving average is $14.06. Eloxx Pharmaceuticals has a 12 month low of $8.20 and a 12 month high of $19.96. The company has a market capitalization of $12.49 million, a price-to-earnings ratio of -11.79 and a beta of -1,864.08.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ELOX shares. Wall Street Zen raised Eloxx Pharmaceuticals to a “hold” rating in a research note on Saturday, August 1st. Guggenheim began coverage on Eloxx Pharmaceuticals in a research report on Monday, July 20th. They set a “buy” rating and a $43.00 target price on the stock. Lifesci Capital assumed coverage on Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 target price on the stock. Finally, Weiss Ratings started coverage on Eloxx Pharmaceuticals in a report on Friday, August 14th. They set a “sell (d)” rating for the company. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $41.50.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.